Xeris Biopharma

Q2 FY2026 EarningsQ2 FY2026 outperformed consensus on the top-line with total revenue of $92.1M vs. $90.1M expected, driven by Recorlev's 81% YoY growth. Gross margin of 86% was slightly below the 87.04% mean estimate but represented a significant expansion from 82% YoY. GAAP EPS was a miss at -$0.18 vs. $0.003 expected due to a $31M one-time debt-related charge. Full-year revenue guidance was tightened to $385M–$390M, signaling confidence in sustained commercial momentum.